PANGAEA BIOTECH, S.L. Patent applications |
Patent application number | Title | Published |
20150038520 | Molecular Biomarkers for Predicting Response to Tyrosine Kinase Inhibitors in Lung Cancer - The invention relates to methods for determining the clinical outcome of patients suffering lung cancer and being under treatment with an EGFR inhibitor. The methods are based on the detection of the presence of mutations in the EGFR gene conferring resistance to inhibitors of the EGFR tyrosine kinase activity, wherein the appearance of said mutations in the biofluid of the patient is indicative of a high probability that the patient suffers a relapse of the disease. The invention also provides therapeutic methods for said patients. | 02-05-2015 |
20120316187 | MOLECULAR BIOMARKERS FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITORS IN LUNG CANCER - The invention relates to a method for predicting the response to the treatment with an EGFR tyrosine kinase inhibitor of a patient suffering lung cancer an carrying a mutation in the EGFR gene based on the expression levels in a sample of said patient of the BRCA1 gene wherein low BRCA1 expression levels are indicative of a positive response of a patient. This positive response is also observed in patients showing the T790M mutation in the EGFR gene which is usually associated with resistance to EGFR tyrosine kinase inhibitors. | 12-13-2012 |